aspirin has been researched along with Substance Withdrawal Syndrome in 48 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed a clinical trial to obtain dose-ranging, efficacy, and aspirin-withdrawal data on tiopinac in patients with rheumatoid arthritis." | 9.05 | Tiopinac in rheumatoid arthritis: a three-phase dose-ranging, efficacy, and aspirin-withdrawal protocol. ( Atwater, EC; Francetić, I; Hasday, JD; Jacox, RF; Weintraub, M, 1980) |
| "This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy." | 8.80 | Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998) |
| "Aspirin was administered for vascular event prevention." | 5.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| "We designed a clinical trial to obtain dose-ranging, efficacy, and aspirin-withdrawal data on tiopinac in patients with rheumatoid arthritis." | 5.05 | Tiopinac in rheumatoid arthritis: a three-phase dose-ranging, efficacy, and aspirin-withdrawal protocol. ( Atwater, EC; Francetić, I; Hasday, JD; Jacox, RF; Weintraub, M, 1980) |
| "A large-scale, double-blind comparative study was carried out in general practice to assess the relative efficacy and tolerance of difunisal and aspirin in patients suffering from acute painful conditions such as sprains and trains, osteoarthritis, etc." | 5.04 | Difunisal in general practice. ( Huskisson, EC; Kerry, J; Shaw, LD; Williams, TN, 1978) |
| "This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy." | 4.80 | Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998) |
| " Aspirin was injected at 100 mg/kg, 1 mg/kg and at several different aspirin dilutions along with cyclooxygenase (COX) 1 (SC-560), COX 2 (NS-398) or both selective inhibitors simultaneously using a laser-induced thrombosis model." | 3.76 | Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. ( Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2010) |
| "We studied the effects of ultra-low-dose aspirin (ULDA) as well as those of sc-560 and ns-398, specific COX-1 and COX-2 inhibitors, on induced hemorrhagic time and in a model of laser-induced thrombosis in rats." | 3.74 | Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition? ( Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2007) |
| "Heparin is an effective, widely used treatment for unstable angina." | 2.67 | Reactivation of unstable angina after the discontinuation of heparin. ( Juneau, M; Lam, J; McCans, J; Théroux, P; Waters, D, 1992) |
| " However, recent studies indicate that even discontinuation of long-term use of clopidogrel may be associated with multiple adverse outcomes, that is, rebound phenomenon whose mechanism is not definitely clear." | 1.40 | Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. ( Djukanovic, N; Njegomirovic, S; Obradovic, S; Ostojic, M; Protić, D; Todorovic, Z; Zamaklar-Trifunovic, D, 2014) |
| "Aspirin was administered for vascular event prevention." | 1.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (29.17) | 18.7374 |
| 1990's | 8 (16.67) | 18.2507 |
| 2000's | 18 (37.50) | 29.6817 |
| 2010's | 7 (14.58) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, RL | 1 |
| Pessolano, AA | 1 |
| Shen, TY | 1 |
| Jacobus, DP | 1 |
| Jones, H | 1 |
| Lotti, VJ | 1 |
| Flataker, LM | 1 |
| Kim, J | 1 |
| Jang, HJ | 1 |
| Schellingerhout, D | 1 |
| Lee, SK | 1 |
| Kim, H | 1 |
| Kim, YD | 1 |
| Lee, KY | 1 |
| Choi, HY | 1 |
| Cho, HJ | 1 |
| Jang, SS | 1 |
| Jeon, S | 1 |
| Kwon, IC | 1 |
| Kim, K | 1 |
| Ryu, WS | 1 |
| Nahrendorf, M | 1 |
| Choi, S | 1 |
| Kim, DE | 1 |
| Doutremepuich, C | 4 |
| Aguejouf, O | 4 |
| Desplat, V | 4 |
| Eizayaga, FX | 3 |
| Djukanovic, N | 1 |
| Todorovic, Z | 1 |
| Obradovic, S | 1 |
| Njegomirovic, S | 1 |
| Zamaklar-Trifunovic, D | 1 |
| Protić, D | 1 |
| Ostojic, M | 1 |
| Alcock, RF | 1 |
| Reddel, CJ | 1 |
| Pennings, GJ | 1 |
| Hillis, GS | 1 |
| Curnow, JL | 1 |
| Brieger, DB | 1 |
| Eizayaga, F | 1 |
| Belon, P | 1 |
| Graw, J | 1 |
| Schwenk, W | 1 |
| Volk, T | 1 |
| Jähne, J | 2 |
| Schirren, J | 2 |
| Rottbauer, W | 1 |
| Katus, HA | 1 |
| Bölükbas, S | 1 |
| Martens, A | 1 |
| Haverich, A | 1 |
| Reidenberg, MM | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Tsukada, YT | 1 |
| Senior, K | 1 |
| Albaladejo, P | 1 |
| Geeraerts, T | 1 |
| Francis, F | 1 |
| Castier, Y | 1 |
| Lesèche, G | 1 |
| Marty, J | 1 |
| Dregelid, E | 1 |
| Laxdal, E | 1 |
| Pedersen, G | 1 |
| Aune, S | 1 |
| Angiolillo, DJ | 1 |
| Fernandez-Ortiz, A | 1 |
| Bernardo, E | 1 |
| Ramírez, C | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Llinas, RH | 1 |
| Brennan, MT | 1 |
| Wynn, RL | 1 |
| Miller, CS | 1 |
| Röggla, G | 1 |
| Moser, B | 1 |
| Rossi, ML | 1 |
| Zavalloni, D | 1 |
| Gasparini, GL | 1 |
| Presbitero, P | 1 |
| Weintraub, M | 1 |
| Francetić, I | 1 |
| Hasday, JD | 1 |
| Jacox, RF | 1 |
| Atwater, EC | 1 |
| Schulman, SP | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Topol, EJ | 1 |
| Califf, RM | 1 |
| Navetta, FI | 1 |
| Willerson, JT | 1 |
| Chandra, NC | 1 |
| Guerci, AD | 1 |
| Ferguson, JJ | 1 |
| Harrington, RA | 1 |
| Lincoff, AM | 1 |
| Yakubov, SJ | 1 |
| Bray, PF | 1 |
| Bahr, RD | 1 |
| Wolfe, CL | 1 |
| Yock, PG | 1 |
| Anderson, HV | 1 |
| Nygaard, TW | 1 |
| Mason, SJ | 1 |
| Effron, MB | 1 |
| Fatterpacker, A | 1 |
| Raskin, S | 1 |
| Smith, J | 1 |
| Brashears, L | 1 |
| Gottdiener, P | 1 |
| du Mee, C | 1 |
| Kitt, MM | 1 |
| Gerstenblith, G | 1 |
| Stiegler, H | 1 |
| Noto, T | 1 |
| Nagasaki, M | 1 |
| Yomota, E | 1 |
| Endo, T | 1 |
| Kosten, TR | 1 |
| Mitchell, SM | 1 |
| Sethia, KK | 1 |
| Bachman, DS | 1 |
| Gardos, G | 1 |
| Essigman, WK | 1 |
| Chamberlain, MA | 1 |
| Wright, V | 1 |
| Huskisson, EC | 1 |
| Williams, TN | 1 |
| Shaw, LD | 1 |
| Kerry, J | 1 |
| Jestico, J | 1 |
| Harrison, MJ | 1 |
| Marshall, J | 1 |
| Fenner, H | 1 |
| Hale, RL | 1 |
| Randall, CL | 1 |
| Becker, HC | 1 |
| Turner, KP | 1 |
| Thibault, GE | 1 |
| Théroux, P | 1 |
| Waters, D | 1 |
| Lam, J | 1 |
| Juneau, M | 1 |
| McCans, J | 1 |
| Segarnick, DJ | 1 |
| Cordasco, DM | 1 |
| Rotrosen, J | 1 |
| Louwerenburg, JW | 1 |
| Suttorp, MJ | 1 |
| Herie Kingma, J | 1 |
| Weintraub, SJ | 1 |
| Naulty, JS | 1 |
| Vida, JA | 1 |
| Samour, CM | 1 |
| O'Dea, MH | 1 |
| Wang, TS | 1 |
| Maruyama, Y | 1 |
| Hayashi, G | 1 |
| Smits, SE | 1 |
| Takemori, AE | 1 |
| Buckett, WR | 1 |
| Miller, RR | 1 |
| Feingold, A | 1 |
| Paxinos, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
4 reviews available for aspirin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
Aspirin and bleeding in dentistry: an update and recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Dental C | 2007 |
Pharmacotherapy of cerebral ischemia in cocaine dependence.
Topics: Aspirin; Brain; Brain Ischemia; Cerebrovascular Circulation; Cocaine; Cocaine-Related Disorders; Cog | 1998 |
Propoxyphene hydrochloride. A critical review.
Topics: Analgesics; Aspirin; Caffeine; Clinical Trials as Topic; Codeine; Dextropropoxyphene; Female; Headac | 1970 |
7 trials available for aspirin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Tiopinac in rheumatoid arthritis: a three-phase dose-ranging, efficacy, and aspirin-withdrawal protocol.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Dib | 1980 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
Diflunisal in osteoarthrosis of the hip and knee.
Topics: Adult; Aged; Analgesics; Aspirin; Biphenyl Compounds; Bone Diseases; Clinical Trials as Topic; Femal | 1978 |
Difunisal in general practice.
Topics: Analgesics; Aspirin; Biphenyl Compounds; Clinical Trials as Topic; Family Practice; Female; Humans; | 1978 |
Reactivation of unstable angina after the discontinuation of heparin.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He | 1992 |
Studies on the relationship between 5-hydroxytryptamine turnover in brain and tolerance and physical dependence in mice.
Topics: Animals; Aspirin; Brain; Cyclazocine; Drug Tolerance; Fenclonine; Humans; Levorphanol; Male; Methado | 1971 |
Propoxyphene hydrochloride. A critical review.
Topics: Analgesics; Aspirin; Caffeine; Clinical Trials as Topic; Codeine; Dextropropoxyphene; Female; Headac | 1970 |
38 other studies available for aspirin and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammation; Mice; Naloxone; Pyri | 1978 |
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
Topics: Aged; Aged, 80 and over; Animals; Antithrombins; Arachidonic Acid; Aspirin; Carotid Artery Thrombosi | 2021 |
Aspirin discontinuation syndromes: clinical implications of basic research studies.
Topics: Animals; Aspirin; Biomedical Research; Dose-Response Relationship, Drug; Male; Mice; Mice, Knockout; | 2013 |
Clopidogrel cessation triggers aspirin rebound in patients with coronary stent.
Topics: Aspirin; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Percutaneous Coronary In | 2014 |
The rebound phenomenon after aspirin cessation: the biochemical evidence.
Topics: Adult; Aspirin; Biochemical Phenomena; Female; Humans; Male; Platelet Aggregation Inhibitors; Prospe | 2014 |
Prothrombotic and hemorrhagic effects of aspirin.
Topics: Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhage; Rats; Substa | 2009 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response | 2010 |
Drug discontinuation effects are part of the pharmacology of a drug.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Awards and Prizes; Cardiovascular Age | 2011 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
[Adverse effects of cardiovascular agents in Japan--update 2012].
Topics: Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Aspirin; Benzazepines; Cardiovascular Age | 2012 |
Aspirin withdrawal increases risk of heart problems.
Topics: Aspirin; Coronary Disease; Heart Diseases; Humans; Substance Withdrawal Syndrome | 2003 |
Aspirin withdrawal and acute lower limb ischemia.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Chronic Disease; Female; Humans; Isch | 2004 |
[Should acetylsalicylic acid be withdrawn prior to surgery?].
Topics: Aspirin; Blood Loss, Surgical; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Su | 2005 |
Rebound risk: aspirin and statin withdrawal.
Topics: Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Factors | 2005 |
Aspirin: quitting cold turkey could be dangerous. Studies have linked aspirin withdrawal to heart attacks.
Topics: Aspirin; Brain; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorr | 2005 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
Could discontinuation of aspirin therapy be a trigger for stroke?
Topics: Aspirin; Humans; Ischemia; Platelet Aggregation Inhibitors; Risk; Stroke; Substance Withdrawal Syndr | 2006 |
Seizures in a night club.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Beverages; Caffeine; Drug Interactions | 2007 |
Very late multivessel thrombosis of bare metal stents with concomitant patent drug-eluting stents after withdrawal of aspirin.
Topics: Aspirin; Drug-Eluting Stents; Humans; Male; Middle Aged; Radiography; Stents; Substance Withdrawal S | 2008 |
Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?
Topics: Animals; Aspirin; Bleeding Time; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2007 |
[Recurrent infarct during aspirin therapy].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Dose-Response Relationship, Drug; | 1997 |
Gastric mucosal function following withdrawal of omeprazole in rats.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Ulcer Agents; Aspirin; Gastric Acid; Gastric Mucosa; Gastrin | 1998 |
Hazards of aspirin withdrawal before transurethral prostatectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Humans; Male; Platelet Aggregation Inhibitors; Preoperative Care; | 1999 |
Discontinuing chronic aspirin therapy: another risk factor for stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Prospectiv | 2002 |
Dyskinesia after discountinuation of compound analgesic containing oxycodone.
Topics: Aspirin; Caffeine; Codeine; Drug Combinations; Female; Humans; Middle Aged; Movement Disorders; Oxyc | 1977 |
Trial of aspirin during weaning patients with transient ischaemic attacks from anticoagulants.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Substance Withdrawal Syndrome; Warfarin | 1978 |
[The problems of the various characteristics of drug abuse (author's transl)].
Topics: Alcoholism; Analgesics; Animals; Aspirin; Humans; Hypnotics and Sedatives; Nonprescription Drugs; Pr | 1976 |
Aspirin pretreatment reduces ethanol withdrawal severity in a mouse model of binge drinking.
Topics: Alcoholism; Animals; Aspirin; Body Weight; Disease Models, Animal; Ethanol; Male; Mice; Mice, Inbred | 1992 |
The landlady confirms the diagnosis.
Topics: Acidosis; Adult; Aspirin; Decision Making; Diagnosis, Differential; Drug Overdose; Ethanol; Humans; | 1992 |
Prostanoid modulation (mediation?) of certain behavioral effects of ethanol.
Topics: Alcoholism; Alprostadil; Animals; Aspirin; Brain; Ethanol; Fatty Acids; Fatty Acids, Essential; Fatt | 1985 |
Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Su | 1987 |
Acute abstinence syndrome after epidural injection of butorphanol.
Topics: Adult; Anesthesia, Epidural; Aspirin; Blood Pressure; Butorphanol; Caffeine; Cesarean Section; Codei | 1985 |
Analgesics. 2. Selected 5-substituted 5-(1-phenylethyl)barbituric acids.
Topics: Administration, Oral; Aminopyrine; Analgesics; Animals; Aspirin; Barbiturates; Central Nervous Syste | 1974 |
A new test for morphine-like physical dependence (addiction liability) in rats.
Topics: Aminopyrine; Animals; Aspirin; Atropine; Behavior, Animal; Codeine; Heroin; Histamine H1 Antagonists | 1964 |